Table 2.
Urinary biomarkers in renal cell carcinoma patients on and off VEGF inhibitors with median (IQR) and p value for comparison by Wilcoxon test
| Biomarker | VEGF inhibitor (N=40) | Non- VEGF inhibitor controls (N=40) | P value |
|---|---|---|---|
| NOx /Cr, umol/mg | 0.46 (0.31–0.71) | 0.62 (0.42–0.84) | 0.09 |
| cGMP/Cr, pmol/ug | 0.28 (0.21–0.39) | 0.39 (0.30–0.62) | 0.01 |
| PGE2/Cr, pg/ug | 1.20 (0.79–2.00) | 1.31 (0.99–1.69) | 0.67 |
| cAMP/Cr, pmol/ug | 5.05 (4.60–7.19) | 5.12 (3.88–6.17) | 0.25 |
| 6-keto PGF 1α/Cr, pg/ug | 1.08 (0.87–1.59) | 1.13 (0.75–1.55) | 0.67 |
| ACR, mg/g | 18.4 (5.1–236.2) | 4.6 (0–35.6) | 0.009 |
VEGF denotes vascular endothelial growth factor; IQR, interquartile range; NOx, nitric oxide; Cr, creatinine; cGMP, cyclic GMP; PGE2, prostaglandin E2; cAMP, cyclic AMP; ACR, albumin:creatinine ratio